Monday, November 23, 2026

Domestic Researchers Find Key Switch That Could Break the Alzheimer’s Vicious Cycle

Input
2026-08-27 00:00:00
Updated
2026-08-27 00:00:00
Provided by the Ministry of Science and ICT

[Financial News] A key factor that accelerates the vicious cycle of Alzheimer's disease (AD) has been identified. The findings open the possibility of a new treatment strategy that could ease multiple pathological changes at once by regulating a single target.
The Ministry of Science and ICT said on the 27th that a research team led by Jung Won-seok, deputy head of the Institute for Basic Science (IBS) Center for Vascular Research and associate professor in the Department of Biological Sciences at Korea Advanced Institute of Science and Technology (KAIST), identified a key regulatory factor that disrupts neural circuits and synaptic balance in AD, thereby worsening the disease in a chain reaction.
The study was carried out through the Ministry of Science and ICT's IBS basic science research support program and was published at 12:00 a.m. KST on Aug. 27 in the world's most prestigious international journal, Nature.
The researchers focused on the imbalance in neural circuits and synapses that appears from the early stages of the disease. In analyses of the hippocampus of AD model mice, excitatory neurons that stimulate brain circuits were found to be overactive, while the activity of inhibitory neurons that suppress them dropped sharply. In addition, non-neuronal astrocytes and microglia excessively eliminated excitatory synapses, while removing fewer inhibitory synapses, further deepening the imbalance in neural circuits.
The team found that the root cause of this imbalance in synapse loss ultimately lies in the abnormal activation state of neurons. When neuronal activity was artificially increased, glial cells removed more synapses; when activity was reduced, they removed fewer.
Based on this, the researchers traced the molecular cause and found that the ERBB4 receptor, which exists in inhibitory neurons in the healthy brain, was markedly increased in a specific population of excitatory neurons. They named these cells early responsive excitatory neurons (ERENs) and identified ERBB4 as a key factor driving circuit abnormalities. ERBB4, or erb-b2 receptor tyrosine kinase 4, is a receptor protein that senses external signals at the cell membrane and regulates cell growth, differentiation, and neuronal function.
The team then used gene-editing technology to selectively remove ERBB4 only from excitatory neurons in AD model mice. As a result, the overactivity of excitatory neurons was reduced, and the activity of some previously suppressed inhibitory neurons was restored. Abnormal synapse elimination and inflammatory responses by glial cells were also eased, while the area and number of amyloid plaques fell by more than 50%. Memory and spatial cognition also improved significantly.
Conversely, when ERBB4 was expressed in excitatory neurons of normal mice, the same pathological changes seen in AD appeared even in the complete absence of amyloid plaques, including neural hyperexcitability, synaptic imbalance, and inflammatory responses from glial cells.
The researchers also demonstrated the mechanism by which increased ERBB4 causes pathology to spread to surrounding areas by excessively activating the mTOR signaling pathway, which regulates cell growth and metabolism. In an analysis of brain tissue from 446 people, ERBB4 expression in excitatory neurons of AD patients was significantly elevated, and higher expression levels were associated with greater amyloid plaque accumulation and more severe cognitive decline. mTOR is an intracellular signaling protein that regulates a wide range of biological processes, including cell growth, metabolism, and protein synthesis.
This confirms that changes in ERBB4 are not merely a phenomenon accompanying AD, but a key regulatory factor that promotes the chain progression of multiple pathological changes.
Jung Won-seok, deputy head of the IBS Center for Vascular Research, said, "We expect this to contribute to the development of a new therapeutic strategy that targets the core link in the disease's vicious cycle and simultaneously alleviates complex and diverse pathologies."
[email protected] Youn Ji-an Reporter